Αποτελέσματα Αναζήτησης
Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.
16 Ιουν 2022 · Several vaccines against COVID-19 use nanoparticles to protect the antigen cargo (either proteins or nucleic acids), increase the immunogenicity and ultimately the efficacy.
11 Αυγ 2021 · Nature Nanotechnology - Almost all currently used vaccines against COVID-19 consist of either non-viral or viral nanoparticles. Here we attempt to understand the reasons behind the success of...
2 Σεπ 2021 · The SARS-CoV-2 pandemic has heralded a coming-of-age for vaccine nanotechnology. Decades of groundwork optimizing new vaccine platforms allowed clinical trials with nanoparticle vaccine candidates to begin within 2 months of the SARS-CoV-2 genome sequence being made publicly available.
1 Φεβ 2023 · Updated vaccines. To tackle SARS-CoV-2 variants, the vaccine developers Pfizer–BioNTech and Moderna introduced updated mRNA vaccines last year. These are called bivalent, because they encode...
7 Ιουλ 2022 · The current study investigates the effectiveness of said TiO 2 nanostructured surfaces against two enveloped human coronaviruses, SARS-CoV-2 and HCoV-NL63, and nonenveloped HRV-16 for surface-based inactivation.
19 Αυγ 2022 · All of the current COVID-19 vaccines in the U.S., and the nanoparticle vaccines, use the spike gene from the original Wuhan strain of SARS-CoV-2, the virus that causes COVID-19. The difference is in how the spike proteins show up.
